Your browser doesn't support javascript.
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario.
Cantini, L; Mentrasti, G; Russo, G L; Signorelli, D; Pasello, G; Rijavec, E; Russano, M; Antonuzzo, L; Rocco, D; Giusti, R; Adamo, V; Genova, C; Tuzi, A; Morabito, A; Gori, S; Verde, N La; Chiari, R; Cortellini, A; Cognigni, V; Pecci, F; Indini, A; De Toma, A; Zattarin, E; Oresti, S; Pizzutilo, E G; Frega, S; Erbetta, E; Galletti, A; Citarella, F; Fancelli, S; Caliman, E; Della Gravara, L; Malapelle, U; Filetti, M; Piras, M; Toscano, G; Zullo, L; De Tursi, M; Di Marino, P; D'Emilio, V; Cona, M S; Guida, A; Caglio, A; Salerno, F; Spinelli, G; Bennati, C; Morgillo, F; Russo, A; Dellepiane, C; Vallini, I.
  • Cantini L; Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy. Electronic address: https://twitter.com/LucaCantiniMD.
  • Mentrasti G; Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy.
  • Russo GL; Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
  • Signorelli D; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Pasello G; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy.
  • Rijavec E; Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Russano M; Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy.
  • Antonuzzo L; Medical Oncology Unit, Careggi University Hospital, Florence, Italy.
  • Rocco D; Department of Pulmonology and Oncology, AORN dei Colli Monaldi, Naples, Italy.
  • Giusti R; UOC Oncologia Medica, Azienda Ospedaliero Universitaria Sant'Andrea, Università La Sapienza, Rome, Italy.
  • Adamo V; Oncologia Medica, A.O.Papardo & Università di Messina, Messina, Italy.
  • Genova C; UOC Clinica di Oncologia Medica, IRCCS Ospedale San Martino, Department of Internal Medicine and Medical Specialties (DIMI), Università degli Studi di Genova, Genoa, Italy.
  • Tuzi A; Oncologia Medica, ASST Sette Laghi, Varese, Italy.
  • Morabito A; Thoracic Medical Oncology, Istituto Nazionale Tumori "Fondazione G Pascale", IRCCS, Naples, Italy.
  • Gori S; UOC Oncologia Medica, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Verona, Italy.
  • Verde N; Department of Oncology, Ospedale Luigi Sacco, ASST Fatebenefratelli Sacco, Milan, Italy.
  • Chiari R; Medical Oncology, Ospedali Riuniti Padova Sud, Monselice, Italy.
  • Cortellini A; Medical Oncology, St Salvatore Hospital, L'Aquila, Italy.
  • Cognigni V; Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy.
  • Pecci F; Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy.
  • Indini A; Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • De Toma A; Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
  • Zattarin E; Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
  • Oresti S; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.
  • Pizzutilo EG; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.
  • Frega S; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy.
  • Erbetta E; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy.
  • Galletti A; Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy.
  • Citarella F; Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy.
  • Fancelli S; Medical Oncology Unit, Careggi University Hospital, Florence, Italy.
  • Caliman E; Medical Oncology Unit, Careggi University Hospital, Florence, Italy.
  • Della Gravara L; Dipartment of Experimental Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy.
  • Malapelle U; Department of Public Health, Università degli Studi di Napoli "Federico II", Naples, Italy.
  • Filetti M; UOC Oncologia Medica, Azienda Ospedaliero Universitaria Sant'Andrea, Università La Sapienza, Rome, Italy.
  • Piras M; UOC Oncologia Medica, Azienda Ospedaliero Universitaria Sant'Andrea, Università La Sapienza, Rome, Italy.
  • Toscano G; Oncologia Medica, A.O.Papardo, Messina, Italy.
  • Zullo L; UOC Oncologia Medica 2, IRCCS Ospedale San Martino, Genoa, Italy.
  • De Tursi M; Department of Innovative Technologies in Medicine & Dentistry, Università G. D'Annunzio, Chieti-Pescara, Chieti, Italy.
  • Di Marino P; Department of Innovative Technologies in Medicine & Dentistry, Università G. D'Annunzio, Chieti-Pescara, Chieti, Italy.
  • D'Emilio V; UOC Pneumologia, Ospedale Mazzoni, Ascoli Piceno, Italy.
  • Cona MS; Department of Oncology, Ospedale Luigi Sacco, ASST Fatebenefratelli Sacco, Milan, Italy.
  • Guida A; Oncologia Medica e Traslazionale, AO Santa Maria, Terni, Italy.
  • Caglio A; Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, Italy.
  • Salerno F; Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, Italy.
  • Spinelli G; UOC Territorial Oncology, University "Sapienza", AUSL Latina, Cds Aprilia, Aprilia, Italy.
  • Bennati C; Department of Onco-Hematology, AUSL della Romagna, Ravenna, Italy.
  • Morgillo F; UOC Oncologia ed Ematologia, Department of Precision Medicine, Università degli studi della Campania "Luigi Vanvitelli", Naples, Italy.
  • Russo A; Oncologia Medica, A.O.Papardo, Messina, Italy.
  • Dellepiane C; UOC Oncologia Medica 2, IRCCS Ospedale San Martino, Genoa, Italy.
  • Vallini I; Oncologia Medica, ASST Sette Laghi, Varese, Italy.
ESMO Open ; 7(2): 100406, 2022 04.
Article in English | MEDLINE | ID: covidwho-1729762
ABSTRACT

INTRODUCTION:

COVID-19 has disrupted the global health care system since March 2020. Lung cancer (LC) patients (pts) represent a vulnerable population highly affected by the pandemic. This multicenter Italian study aimed to evaluate whether the COVID-19 outbreak had an impact on access to cancer diagnosis and treatment of LC pts compared with pre-pandemic time.

METHODS:

Consecutive newly diagnosed LC pts referred to 25 Italian Oncology Departments between March and December 2020 were included. Access rate and temporal intervals between date of symptoms onset and diagnostic and therapeutic services were compared with the same period in 2019. Differences between the 2 years were analyzed using the chi-square test for categorical variables and the Mann-Whitney U test for continuous variables.

RESULTS:

A slight reduction (-6.9%) in newly diagnosed LC cases was observed in 2020 compared with 2019 (1523 versus 1637, P = 0.09). Newly diagnosed LC pts in 2020 were more likely to be diagnosed with stage IV disease (P < 0.01) and to be current smokers (someone who has smoked more than 100 cigarettes, including hand-rolled cigarettes, cigars, cigarillos, in their lifetime and has smoked in the last 28 days) (P < 0.01). The drop in terms of new diagnoses was greater in the lockdown period (percentage drop -12% versus -3.2%) compared with the other months included. More LC pts were referred to a low/medium volume hospital in 2020 compared with 2019 (P = 0.01). No differences emerged in terms of interval between symptoms onset and radiological diagnosis (P = 0.94), symptoms onset and cytohistological diagnosis (P = 0.92), symptoms onset and treatment start (P = 0.40), and treatment start and first radiological revaluation (P = 0.36).

CONCLUSIONS:

Our study pointed out a reduction of new diagnoses with a shift towards higher stage at diagnosis for LC pts in 2020. Despite this, the measures adopted by Italian Oncology Departments ensured the maintenance of the diagnostic-therapeutic pathways of LC pts.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Lung Neoplasms Type of study: Diagnostic study / Experimental Studies / Observational study Limits: Humans Country/Region as subject: Europa Language: English Journal: ESMO Open Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Lung Neoplasms Type of study: Diagnostic study / Experimental Studies / Observational study Limits: Humans Country/Region as subject: Europa Language: English Journal: ESMO Open Year: 2022 Document Type: Article